Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$7.79 USD

7.79
1,013,423

+0.04 (0.52%)

Updated May 10, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AllScripts Healthcare (MDRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allscripts' (MDRX) Solution Gets Selected by Revo Health

by Zacks Equity Research

Allscripts' (MDRX) Practice Management solution to improve financial and operational performance of all i-Health clinics of Revo Health.

Allscripts' (MDRX) Sunrise Platform Picked by Mercy Iowa City

by Zacks Equity Research

Allscripts' (MDRX) Sunrise platform gets selected by Mercy Iowa City, thereby enabling the former to help in delivering better patient outcomes and accelerating the future of healthcare.

AllScripts (MDRX) Down 2.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Allscripts (MDRX) stock, courtesy of solid prospects.

Allscripts (MDRX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Allscripts (MRDX) witnessed expansion in gross margin, driven by better-than-expected software revenues and consistent decline in operating expenses.

AllScripts Healthcare (MDRX) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

AllScripts (MDRX) delivered earnings and revenue surprises of 31.82% and 1.86%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect weak segmental performance.

Can AllScripts (MDRX) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

AllScripts (MDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics

by Zacks Equity Research

Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics

Urmimala Biswas headshot

3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis

by Urmimala Biswas

Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Information industry. OMCL, NXGN and NH are well positioned to gain.

Allscripts (MDRX) Extends Tie-Up With US Orthopedic Alliance

by Zacks Equity Research

Allscripts (MDRX) extends strategic partnership with US Orthopedic Alliance to form a more scalable orhopedic services technology platform.

Sriparna Ghosal headshot

3 Biggest MedTech Trends to Watch in 2021 for Better Returns

by Sriparna Ghosal

Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.

Sriparna Ghosal headshot

3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021

by Sriparna Ghosal

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

Allscripts (MDRX) Completes Sale of CarePort Health Business

by Zacks Equity Research

Allscripts' (MDRX) agreement with WellSky empowers providers with efficient care transitions and better patient health outcomes.

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Allscripts (MDRX) stock on the back of its solid prospects.

    Debanjana Dey headshot

    3 Telemedicine Stocks to Gain in 2021 on Digital Health Boom

    by Debanjana Dey

    Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.

    Allscripts' (MDRX) Veradigm Collaborates With HealthVerity

    by Zacks Equity Research

    Allscripts (MDRX) and HealthVerity will be committed toward catering to specific industry needs by helping clients design linked data solutions that are fit-for-purpose.

    Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat

    by Zacks Equity Research

    Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.

    AllScripts Healthcare (MDRX) Q3 Earnings Surpass Estimates

    by Zacks Equity Research

    AllScripts (MDRX) delivered earnings and revenue surprises of 11.11% and -4.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    AllScripts Healthcare (MDRX) Reports Next Week: Wall Street Expects Earnings Growth

    by Zacks Equity Research

    AllScripts (MDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Allscripts Completes Sale of EPSi Business to Strata

    by Zacks Equity Research

    Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.

    Urmimala Biswas headshot

    3 Sectors Areas to Invest in Ahead of Q3 Earnings

    by Urmimala Biswas

    Here is a rundown of how sectors like digital health, consumer staple and e-learning have performed in the third quarter of 2020.

    MDRX vs. HMSY: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    MDRX vs. HMSY: Which Stock Is the Better Value Option?

    Veeva's Vault eTMF Gets Implemented by Biotest for Trials

    by Zacks Equity Research

    Veeva's (VEEV) Vault eTMF should enable Biotest to manage all study documents and activities in real time.